newsfilter
← Latest News
Business Wire·

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 — — Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025